Sina Bavari

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1640831/publications.pdf

Version: 2024-02-01

328 papers	20,458 citations	13099 68 h-index	15266 126 g-index
342 all docs	342 docs citations	342 times ranked	22758 citing authors

#	Article	IF	Citations
1	Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature, 2016, 531, 381-385.	27.8	1,245
2	Identification of Oxidative Stress and Toll-like Receptor 4 Signaling as a Key Pathway of Acute Lung Injury. Cell, 2008, 133, 235-249.	28.9	1,164
3	Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. Journal of Medicinal Chemistry, 2017, 60, 1648-1661.	6.4	547
4	Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature, 2014, 508, 402-405.	27.8	520
5	Distinct Patterns of IFITM-Mediated Restriction of Filoviruses, SARS Coronavirus, and Influenza A Virus. PLoS Pathogens, 2011, 7, e1001258.	4.7	518
6	Lipid Raft Microdomains. Journal of Experimental Medicine, 2002, 195, 593-602.	8.5	419
7	Taxonomy of the order Mononegavirales: update 2016. Archives of Virology, 2016, 161, 2351-2360.	2.1	407
8	Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2880-2885.	7.1	401
9	Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4133-42.	7.1	320
10	Ebola and Marburg Viruses Replicate in Monocyteâ€Derived Dendritic Cells without Inducing the Production of Cytokines and Full Maturation. Journal of Infectious Diseases, 2003, 188, 1630-1638.	4.0	268
11	Reemergence of Monkeypox: Prevalence, Diagnostics, and Countermeasures. Clinical Infectious Diseases, 2005, 41, 1765-1771.	5.8	261
12	L1000CDS2: LINCS L1000 characteristic direction signatures search engine. Npj Systems Biology and Applications, 2016, 2, .	3.0	250
13	Ebola Virusâ€Like Particleâ€“Based Vaccine Protects Nonhuman Primates against Lethal Ebola Virus Challenge. Journal of Infectious Diseases, 2007, 196, S430-S437.	4.0	236
14	Ebola virus-like particles protect from lethal Ebola virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 15889-15894.	7.1	231
15	Taxonomy of the order Mononegavirales: update 2019. Archives of Virology, 2019, 164, 1967-1980.	2.1	224
16	A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents. PLoS ONE, 2013, 8, e60579.	2.5	223
17	Evaluation of Ebola Virus Inhibitors for Drug Repurposing. ACS Infectious Diseases, 2015, 1, 317-326.	3.8	209
18	In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 15936-15941.	7.1	194

#	Article	IF	Citations
19	Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nature Medicine, 2010, 16, 991-994.	30.7	189
20	2020 taxonomic update for phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2020, 165, 3023-3072.	2.1	184
21	Vaccine adjuvant uses of poly-IC and derivatives. Expert Review of Vaccines, 2015, 14, 447-459.	4.4	183
22	Taxonomy of the order Mononegavirales: update 2017. Archives of Virology, 2017, 162, 2493-2504.	2.1	173
23	3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13336-13341.	7.1	169
24	Broad-spectrum coronavirus antiviral drug discovery. Expert Opinion on Drug Discovery, 2019, 14, 397-412.	5.0	168
25	Zika Virus: Medical Countermeasure Development Challenges. PLoS Neglected Tropical Diseases, 2016, 10, e0004530.	3.0	159
26	Rational design of small molecules as vaccine adjuvants. Science Translational Medicine, 2014, 6, 263ra160.	12.4	153
27	Taxonomy of the order Mononegavirales: update 2018. Archives of Virology, 2018, 163, 2283-2294.	2.1	153
28	BCX4430 â€“ A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. Journal of Infection and Public Health, 2016, 9, 220-226.	4.1	149
29	The evolving field of biodefence: therapeutic developments and diagnostics. Nature Reviews Drug Discovery, 2005, 4, 281-296.	46.4	138
30	Macrophage-Derived Cell Lines Do Not Express Proinflammatory Cytokines after Exposure to Bacillus anthracis Lethal Toxin. Infection and Immunity, 2001, 69, 1175-1177.	2.2	137
31	Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers. PLoS Pathogens, 2006, 2, e1.	4.7	137
32	Identification of small molecule inhibitors of anthrax lethal factor. Nature Structural and Molecular Biology, 2004, 11, 67-72.	8.2	136
33	Role of Natural Killer Cells in Innate Protection against Lethal Ebola Virus Infection. Journal of Experimental Medicine, 2004, 200, 169-179.	8.5	133
34	Induction of Humoral and CD8+ T Cell Responses Are Required for Protection against Lethal Ebola Virus Infection. Journal of Immunology, 2005, 175, 1184-1191.	0.8	126
35	Infectious Lassa Virus, but Not Filoviruses, Is Restricted by BST-2/Tetherin. Journal of Virology, 2010, 84, 10569-10580.	3.4	125
36	Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine, 2005, 23, 3033-3042.	3.8	119

#	Article	IF	Citations
37	VP35 Knockdown Inhibits Ebola Virus Amplification and Protects against Lethal Infection in Mice. Antimicrobial Agents and Chemotherapy, 2006, 50, 984-993.	3.2	119
38	Dendritic Cells Endocytose Bacillus anthracis Spores: Implications for Anthrax Pathogenesis. Journal of Immunology, 2005, 174, 5545-5552.	0.8	117
39	Conserved Receptor-binding Domains of Lake Victoria Marburgvirus and Zaire Ebolavirus Bind a Common Receptor. Journal of Biological Chemistry, 2006, 281, 15951-15958.	3.4	115
40	Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunology and Medical Microbiology, 2004, 40, 27-31.	2.7	113
41	Ebola virus uses clathrin-mediated endocytosis as an entry pathway. Virology, 2010, 401, 18-28.	2.4	110
42	IFITM-2 and IFITM-3 but Not IFITM-1 Restrict Rift Valley Fever Virus. Journal of Virology, 2013, 87, 8451-8464.	3.4	109
43	Protection against Bacterial Superantigen Staphylococcal Enterotoxin B by Passive Vaccination. Infection and Immunity, 2002, 70, 2278-2281.	2.2	106
44	Neglected filoviruses. FEMS Microbiology Reviews, 2016, 40, 494-519.	8.6	106
45	Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses, 2012, 4, 2806-2830.	3.3	105
46	Identification and pathological characterization of persistent asymptomatic Ebola virus infection in rhesus monkeys. Nature Microbiology, 2017, 2, 17113.	13.3	104
47	Neuropathogenesis of Zika Virus in a Highly Susceptible Immunocompetent Mouse Model after Antibody Blockade of Type I Interferon. PLoS Neglected Tropical Diseases, 2017, 11, e0005296.	3.0	103
48	The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus. IScience, 2019, 19, 1279-1290.	4.1	100
49	Development and Characterization of a Mouse Model for Marburg Hemorrhagic Fever. Journal of Virology, 2009, 83, 6404-6415.	3.4	99
50	Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Archives of Virology, 2013, 158, 301-311.	2.1	99
51	Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochemical and Biophysical Research Communications, 2003, 310, 84-93.	2.1	98
52	Inhibition of Metalloprotease Botulinum Serotype A from a Pseudo-peptide Binding Mode to a Small Molecule That Is Active in Primary Neurons. Journal of Biological Chemistry, 2007, 282, 5004-5014.	3.4	98
53	Identification of a Small-Molecule Entry Inhibitor for Filoviruses. Journal of Virology, 2011, 85, 3106-3119.	3.4	98
54	Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology, 2004, 326, 280-287.	2.4	92

#	Article	IF	Citations
55	Crimean-Congo hemorrhagic fever: Current and future prospects of vaccines and therapies. Antiviral Research, 2011, 90, 85-92.	4.1	91
56	Timeâ€Lapse Confocal Imaging of Development ofBacillus anthracisin Macrophages. Journal of Infectious Diseases, 2004, 189, 1313-1316.	4.0	89
57	Development of engineered vaccines effective against structurally related bacterial superantigens. Vaccine, 1998, 16, 1857-1864.	3.8	88
58	HSPA5 is an essential host factor for Ebola virus infection. Antiviral Research, 2014, 109, 171-174.	4.1	88
59	Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine, 2004, 22, 3495-3502.	3.8	87
60	Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Research, 2009, 83, 245-251.	4.1	84
61	Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Research, 2008, 78, 26-36.	4.1	83
62	Nomenclature- and Database-Compatible Names for the Two Ebola Virus Variants that Emerged in Guinea and the Democratic Republic of the Congo in 2014. Viruses, 2014, 6, 4760-4799.	3.3	83
63	Filovirusâ€Like Particles Produced in Insect Cells: Immunogenicity and Protection in Rodents. Journal of Infectious Diseases, 2007, 196, S421-S429.	4.0	79
64	Marburgvirus Hijacks Nrf2-Dependent Pathway by Targeting Nrf2-Negative Regulator Keap1. Cell Reports, 2014, 6, 1026-1036.	6.4	77
65	Functional CD8+ T Cell Responses in Lethal Ebola Virus Infection. Journal of Immunology, 2008, 180, 4058-4066.	0.8	76
66	Identification of an antioxidant small-molecule with broad-spectrum antiviral activity. Antiviral Research, 2012, 93, 23-29.	4.1	76
67	Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus. Antiviral Research, 2018, 151, 97-104.	4.1	76
68	Anthrax Biosensor, Protective Antigen Ion Channel Asymmetric Blockade. Journal of Biological Chemistry, 2005, 280, 34056-34062.	3.4	75
69	High Infection Rates for Adult Macaques after Intravaginal or Intrarectal Inoculation with Zika Virus. Emerging Infectious Diseases, 2017, 23, 1274-1281.	4.3	74
70	Small molecule inhibitors of ER Î±-glucosidases are active against multiple hemorrhagic fever viruses. Antiviral Research, 2013, 98, 432-440.	4.1	72
71	Reactive oxygen species activate NFÎºB (p65) and p53 and induce apoptosis in RVFV infected liver cells. Virology, 2014, 449, 270-286.	2.4	71
72	Protection againstStaphylococcus aureusSepsis by Vaccination with Recombinant Staphylococcal Enterotoxin A Devoid of Superantigenicity. Journal of Infectious Diseases, 1999, 180, 1370-1373.	4.0	70

#	Article	IF	Citations
73	Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. Clinical Immunology, 2003, 108, 51-59.	3.2	70
74	Association of Ebola Virus Matrix Protein VP40 with Microtubules. Journal of Virology, 2005, 79, 4709-4719.	3.4	70
75	Taxonomy of the order Mononegavirales: second update 2018. Archives of Virology, 2019, 164, 1233-1244.	2.1	70
76	Mechanisms and Consequences of Ebolavirus-Induced Lymphocyte Apoptosis. Journal of Immunology, 2010, 184, 327-335.	0.8	69
77	Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice. Vaccine, 2011, 29, 2968-2977.	3.8	69
78	Staphylococcal enterotoxins A and B share a common structural motif for binding class II major histocompatibility complex molecules. Nature Structural Biology, 1995, 2, 554-560.	9.7	68
79	Humanlike Immune Response of Human Leukocyte Antigenâ€“DR3 Transgenic Mice to Staphylococcal Enterotoxins: A Novel Model for Superantigen Vaccines. Journal of Infectious Diseases, 2002, 185, 1754-1760.	4.0	68
80	Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Review of Vaccines, 2008, 7, 417-429.	4.4	68
81	Evaluation of Perceived Threat Differences Posed by Filovirus Variants. Biosecurity and Bioterrorism, 2011, 9, 361-371.	1.2	68
82	Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail. Cell Reports, 2015, 12, 2111-2120.	6.4	68
83	Superantigen Vaccines: A Comparative Study of Genetically Attenuated Receptor-Binding Mutants of Staphylococcal Enterotoxin A. Journal of Infectious Diseases, 1996, 174, 338-345.	4.0	67
84	Identification of Essential Filovirion-associated Host Factors by Serial Proteomic Analysis and RNAi Screen. Molecular and Cellular Proteomics, 2010, 9, 2690-2703.	3.8	66
85	Bacterial superantigens in human disease: structure, function and diversity. Trends in Microbiology, 1995, 3, 463-468.	7.7	65
86	High-Affinity, Protective Antibodies to the Binding Domain of Botulinum Neurotoxin Type A. Infection and Immunity, 2001, 69, 570-574.	2.2	65
87	Chemical Modifications of Antisense Morpholino Oligomers Enhance Their Efficacy against Ebola Virus Infection. Antimicrobial Agents and Chemotherapy, 2009, 53, 2089-2099.	3.2	65
88	Antiviral Activity of a Small-Molecule Inhibitor of Filovirus Infection. Antimicrobial Agents and Chemotherapy, 2010, 54, 2152-2159.	3.2	65
89	African and Asian Zika Virus Isolates Display Phenotypic Differences Both In Vitro and In Vivo. American Journal of Tropical Medicine and Hygiene, 2018, 98, 432-444.	1.4	65
90	Assembly of a functional Machupo virus polymerase complex. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20069-20074.	7.1	64

#	Article	IF	Citations
91	2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2021, 166, 3513-3566.	2.1	62
92	Anthrax Lethal Toxin Impairs Innate Immune Functions of Alveolar Macrophages and Facilitates Bacillus anthracis Survival. Infection and Immunity, 2006, 74, 5029-5034.	2.2	60
93	Humanized mice as a preclinical tool for infectious disease and biomedical research. Annals of the New York Academy of Sciences, 2011, 1245, 50-54.	3.8	59
94	Inhibition of Ebola Virus Entry by a C-peptide Targeted to Endosomes. Journal of Biological Chemistry, 2011, 286, 15854-15861.	3.4	59
95	Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Archives of Virology, 2014, 159, 1229-37.	2.1	59
96	A Single Phosphorodiamidate Morpholino Oligomer Targeting VP24 Protects Rhesus Monkeys against Lethal Ebola Virus Infection. MBio, 2015, 6, .	4.1	59
97	A Refined Pharmacophore Identifies Potent 4-Amino-7-chloroquinoline-Based Inhibitors of the Botulinum Neurotoxin Serotype A Metalloprotease. Journal of Medicinal Chemistry, 2007, 50, 2127-2136.	6.4	58
98	Standardization of the Filovirus Plaque Assay for Use in Preclinical Studies. Viruses, 2012, 4, 3511-3530.	3.3	58
99	Crossâ€Reactive Antibodies Prevent the Lethal Effects ofStaphylococcus aureusSuperantigens. Journal of Infectious Diseases, 1999, 180, 1365-1369.	4.0	57
100	A Potent Peptidomimetic Inhibitor of Botulinum Neurotoxin Serotype A Has a Very Different Conformation than SNAP-25 Substrate. Structure, 2008, 16, 1588-1597.	3.3	57
101	Persistent Marburg Virus Infection in the Testes of Nonhuman Primate Survivors. Cell Host and Microbe, 2018, 24, 405-416.e3.	11.0	55
102	Inhibition of Interleukin 2 Driven Proliferation of Mouse Ctll2 Cells, By Selected Carbamate and Organophosphate Insecticides and Congeners of Carbaryl. Immunopharmacology and Immunotoxicology, 1993, 15, 199-215.	2.4	54
103	Purified Bacillus anthracis Lethal Toxin Complex Formed in Vitro and during Infection Exhibits Functional and Biological Activity. Journal of Biological Chemistry, 2005, 280, 10834-10839.	3.4	54
104	Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Archives of Virology, 2013, 158, 1425-1432.	2.1	54
105	Crimeanâ€“Congo hemorrhagic fever virus utilizes a clathrin- and early endosome-dependent entry pathway. Virology, 2013, 444, 45-54.	2.4	54
106	Development of a model for marburgvirus based on severe-combined immunodeficiency mice. Virology Journal, 2007, 4, 108.	3.4	53
107	The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines. Virus Research, 2021, 292, 198246.	2.2	53
108	Human Leukocyte Antigen-DQ8 Transgenic Mice: a Model To Examine the Toxicity of Aerosolized Staphylococcal Enterotoxin B. Infection and Immunity, 2005, 73, 2452-2460.	2.2	52

#	Article	IF	Citations
109	Novel 4-Aminoquinolines Active against Chloroquine-Resistant and Sensitive P. falciparum Strains that also Inhibit Botulinum Serotype A. Journal of Medicinal Chemistry, 2008, 51, 4388-4391.	6.4	52
110	Development of High-Content Imaging Assays for Lethal Viral Pathogens. Journal of Biomolecular Screening, 2010, 15, 755-765.	2.6	52
111	Alkylated Porphyrins Have Broad Antiviral Activity against Hepadnaviruses, Flaviviruses, Filoviruses, and Arenaviruses. Antimicrobial Agents and Chemotherapy, 2011, 55, 478-486.	3.2	52
112	Discovering Drugs for the Treatment of Ebola Virus. Current Treatment Options in Infectious Diseases, 2017, 9, 299-317.	1.9	51
113	AVI-7288 for Marburg Virus in Nonhuman Primates and Humans. New England Journal of Medicine, 2015, 373, 339-348.	27.0	50
114	Protein Kinase R Degradation Is Essential for Rift Valley Fever Virus Infection and Is Regulated by SKP1-CUL1-F-box (SCF)FBXW11-NSs E3 Ligase. PLoS Pathogens, 2016, 12, e1005437.	4.7	50
115	Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Review of Vaccines, 2016, 15, 1101-1112.	4.4	50
116	Homologous and Heterologous Protection of Nonhuman Primates by Ebola and Sudan Virus-Like Particles. PLoS ONE, 2015, 10, e0118881.	2.5	50
117	Filovirus RefSeq Entries: Evaluation and Selection of Filovirus Type Variants, Type Sequences, and Names. Viruses, 2014, 6, 3663-3682.	3.3	49
118	Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity. EBioMedicine, 2016, 3, 67-78.	6.1	49
119	Screening for Antibacterial Inhibitors of the UDP-3-O-(R-3-Hydroxymyristoyl)- N-Acetylglucosamine Deacetylase (LpxC) Using a High-Throughput Mass Spectrometry Assay. Journal of Biomolecular Screening, 2010, 15, 52-61.	2.6	48
120	Lethal Shock Induced by Streptococcal Pyrogenic Exotoxin A in Mice Transgenic for Human Leukocyte Antigenâ€“DQ8 and Human CD4 Receptors: Implications for Development of Vaccines and Therapeutics. Journal of Infectious Diseases, 2002, 186, 501-510.	4.0	47
121	A Chemotype That Inhibits Three Unrelated Pathogenic Targets: The Botulinum Neurotoxin Serotype A Light Chain,P. falciparumMalaria, and the Ebola Filovirus. Journal of Medicinal Chemistry, 2011, 54, 1157-1169.	6.4	46
122	Filovirus-like particles as vaccines and discovery tools. Expert Review of Vaccines, 2005, 4, 429-440.	4.4	45
123	Human Antibodies to Bacterial Superantigens and Their Ability To Inhibit T-Cell Activation and Lethality. Antimicrobial Agents and Chemotherapy, 2001, 45, 460-463.	3.2	44
124	Novel Broad-Spectrum Bis-(Imidazolinylindole) Derivatives with Potent Antibacterial Activities against Antibiotic-Resistant Strains. Antimicrobial Agents and Chemotherapy, 2009, 53, 4283-4291.	3.2	44
125	Advanced morpholino oligomers: A novel approach to antiviral therapy. Antiviral Research, 2012, 94, 80-88.	4.1	44
126	Sphingosine kinase 2 is a chikungunya virus host factor co-localized with the viral replication complex. Emerging Microbes and Infections, 2015, 4, 1-9.	6.5	44

#	Article	IF	Citations
127	Ebola Virus Genome Plasticity as a Marker of Its Passaging History: A Comparison of In Vitro Passaging to Non-Human Primate Infection. PLoS ONE, 2012, 7, e50316.	2.5	44
128	Analysis of Ebola virus and VLP release using an immunocapture assay. Journal of Virological Methods, 2005, 127, 1-9.	2.1	43
129	NKp30-dependent cytolysis of filovirus-infected human dendritic cells. Cellular Microbiology, 2007, 9, 962-976.	2.1	43
130	Toll-Like Receptor Agonist Augments Virus-Like Particle-Mediated Protection from Ebola Virus with Transient Immune Activation. PLoS ONE, 2014, 9, e89735.	2.5	43
131	Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) Study: Reverse Transcription-Polymerase Chain Reaction and Cataract Surgery Outcomes of Ebola Survivors in Sierra Leone. EBioMedicine, 2018, 30, 217-224.	6.1	42
132	Ebola Virus Inactivation with Preservation of Antigenic and Structural Integrity by a Photoinducible Alkylating Agent. Journal of Infectious Diseases, 2007, 196, S276-S283.	4.0	41
133	Sizing the Bacillus anthracis PA63 Channel with Nonelectrolyte Poly(Ethylene Glycols). Biophysical Journal, 2008, 95, 1157-1164.	0.5	41
134	Ebolavirus Î”-Peptide Immunoadhesins Inhibit Marburgvirus and Ebolavirus Cell Entry. Journal of Virology, 2011, 85, 8502-8513.	3.4	41
135	Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected With Marburg Virus. Journal of Infectious Diseases, 2020, 222, 1894-1901.	4.0	41
136	Involvement of Vacuolar Protein Sorting Pathway in Ebola Virus Release Independent of TSG101 Interaction. Journal of Infectious Diseases, 2007, 196, S264-S270.	4.0	40
137	Will There Be a Cure for Ebola?. Annual Review of Pharmacology and Toxicology, 2017, 57, 329-348.	9.4	40
138	Protective effects of niacinamide in staphylococcal enterotoxin-B-induced toxicity. Toxicology, 1996, 107, 69-81.	4.2	39
139	Molecular mechanisms of filovirus cellular trafficking. Microbes and Infection, 2003, 5, 639-649.	1.9	39
140	Conformational sampling of the botulinum neurotoxin serotype a light chain: implications for inhibitor binding. Bioorganic and Medicinal Chemistry, 2005, 13, 333-341.	3.0	39
141	Pharmacophore-guided lead optimization: The rational design of a non-zinc coordinating, sub-micromolar inhibitor of the botulinum neurotoxin serotype a metalloprotease. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5811-5813.	2.2	39
142	Synthesis and Biological Evaluation of Botulinum Neurotoxin A Protease Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 2264-2276.	6.4	39
143	Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery. Stem Cell Research, 2011, 6, 195-205.	0.7	38
144	Identification of agents effective against multiple toxins and viruses by host-oriented cell targeting. Scientific Reports, 2015, 5, 13476.	3.3	38

#	Article	IF	Citations
145	ARâ€12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus Replication. Journal of Cellular Physiology, 2016, 231, 2286-2302.	4.1	38
146	Ebola Virus-Like Particles Stimulate Type I Interferons and Proinflammatory Cytokine Expression Through the Toll-Like Receptor and Interferon Signaling Pathways. Journal of Interferon and Cytokine Research, 2014, 34, 79-89.	1.2	37
147	Primary Cultures of Embryonic Chicken Neurons for Sensitive Cell-Based Assay of Botulinum Neurotoxin: Implications for Therapeutic Discovery. Journal of Biomolecular Screening, 2007, 12, 370-377.	2.6	36
148	Threeâ€Ðimensional Database Mining Identifies a Unique Chemotype that Unites Structurally Diverse Botulinum Neurotoxin Serotypeâ€…A Inhibitors in a Threeâ€Zone Pharmacophore. ChemMedChem, 2008, 3, 1905-1912.	3.2	36
149	A STAT-1 knockout mouse model for Machupo virus pathogenesis. Virology Journal, 2011, 8, 300.	3.4	36
150	Nucleotide Prodrug GS-5734 Is a Broad-Spectrum Filovirus Inhibitor That Provides Complete Therapeutic Protection Against the Development of Ebola Virus Disease (EVD) in Infected Non-human Primates. Open Forum Infectious Diseases, 2015, 2, .	0.9	36
151	Potentiation of Inhaled Staphylococcal Enterotoxin B-Induced Toxicity by Lipopolysaccharide in Mice. Toxicologic Pathology, 1996, 24, 619-626.	1.8	35
152	Production and Purification of a Recombinant Staphylococcal Enterotoxin B Vaccine Candidate Expressed in Escherichia coli. Protein Expression and Purification, 2002, 24, 302-312.	1.3	35
153	Comparative In Vitro Activity Profiles of Novel Bis-Indole Antibacterials against Gram-Positive and Gram-Negative Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2010, 54, 3974-3977.	3.2	35
154	Correlates of Immunity to Filovirus Infection. Viruses, 2011, 3, 982-1000.	3.3	35
155	BRILIA: Integrated Tool for High-Throughput Annotation and Lineage Tree Assembly of B-Cell Repertoires. Frontiers in Immunology, 2016, 7, 681.	4.8	35
156	Identifying the principal protective antigenic determinants of type A botulinum neurotoxin. Vaccine, 1998, 16, 1850-1856.	3.8	34
157	Machupo Virus Glycoprotein Determinants for Human Transferrin Receptor 1 Binding and Cell Entry. PLoS ONE, 2011, 6, e21398.	2.5	34
158	Key Genomic Changes Necessary for an In Vivo Lethal Mouse Marburgvirus Variant Selection Process. Journal of Virology, 2011, 85, 3905-3917.	3.4	34
159	Discovery of Novel Small-Molecule Inhibitors of LIM Domain Kinase for Inhibiting HIV-1. Journal of Virology, 2017, 91, .	3.4	34
160	DDX3 suppresses type I interferons and favors viral replication during Arenavirus infection. PLoS Pathogens, 2018, 14, e1007125.	4.7	33
161	Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E5158-E5166.	7.1	32
162	Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus. Antiviral Research, 2018, 151, 50-54.	4.1	31

#	Article	IF	Citations
163	Gaining ground: assays for therapeutics against botulinum neurotoxin. Trends in Microbiology, 2010, 18, 164-172.	7.7	30
164	Animal models for ebolavirus countermeasures discovery: what defines a useful model?. Expert Opinion on Drug Discovery, 2015, 10, 685-702.	5.0	30
165	Characterization of Clinical and Immunological Parameters During Ebola Virus Infection of Rhesus Macaques. Viral Immunology, 2015, 28, 32-41.	1.3	30
166	siRNA Screen Identifies Trafficking Host Factors that Modulate Alphavirus Infection. PLoS Pathogens, 2016, 12, e1005466.	4.7	30
167	Filovirius vaccines. Hum Vaccin, 2011, 7, 701-711.	2.4	29
168	Transcriptome analysis of human immune responses following live vaccine strain (LVS) Francisella tularensis vaccination. Molecular Immunology, 2007, 44, 3173-3184.	2.2	28
169	Development of Cell-Based Assays to Measure Botulinum Neurotoxin Serotype A Activity Using Cleavage-Sensitive Antibodies. Journal of Biomolecular Screening, 2010, 15, 42-51.	2.6	28
170	Potent and broad-spectrum antibacterial activity of indole-based bisamidine antibiotics: Synthesis and SAR of novel analogs of MBX 1066 and MBX 1090. Bioorganic and Medicinal Chemistry, 2013, 21, 7790-7806.	3.0	28
171	Second Generation Steroidal 4-Aminoquinolines Are Potent, Dual-Target Inhibitors of the Botulinum Neurotoxin Serotype A Metalloprotease and P. falciparum Malaria. Journal of Medicinal Chemistry, 2014, 57, 4134-4153.	6.4	28
172	Flex-nucleoside analogues â€“ Novel therapeutics against filoviruses. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2800-2802.	2.2	28
173	Inactivated COVID-19 vaccines to make a global impact. Lancet Infectious Diseases, The, 2021, 21, 746-748.	9.1	28
174	High-throughput screen using a single-cell tyrosine phosphatase assay reveals biologically active inhibitors of tyrosine phosphatase CD45. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13972-13977.	7.1	27
175	4-Amino-7-chloroquinolines: Probing Ligand Efficiency Provides Botulinum Neurotoxin Serotype A Light Chain Inhibitors with Significant Antiprotozoal Activity. Journal of Medicinal Chemistry, 2013, 56, 5860-5871.	6.4	27
176	High Content Image-Based Screening of a Protease Inhibitor Library Reveals Compounds Broadly Active against Rift Valley Fever Virus and Other Highly Pathogenic RNA Viruses. PLoS Neglected Tropical Diseases, 2014, 8, e3095.	3.0	27
177	Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization. Vaccine, 2006, 24, 5872-5880.	3.8	26
178	Reduced Expression of CD45 Protein-tyrosine Phosphatase Provides Protection against Anthrax Pathogenesis. Journal of Biological Chemistry, 2009, 284, 12874-12885.	3.4	26
179	Generation and characterization of high affinity human monoclonal antibodies that neutralize staphylococcal enterotoxin B. Journal of Immune Based Therapies and Vaccines, 2010, 8, 9.	2.4	26
180	Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge. PLoS ONE, 2016, 11, e0162446.	2.5	26

#	Article	IF	Citations
181	Identification of a coumarin-based antihistamine-like small molecule as an anti-filoviral entry inhibitor. Antiviral Research, 2017, 145, 24-32.	4.1	26
182	Enhancing the antiviral potency of ER Î±-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo. Antiviral Research, 2018, 150, 112-122.	4.1	26
183	Multi-Faceted Proteomic Characterization of Host Protein Complement of Rift Valley Fever Virus Virions and Identification of Specific Heat Shock Proteins, Including HSP90, as Important Viral Host Factors. PLoS ONE, 2014, 9, e93483.	2.5	26
184	Nonhuman primates as models for the discovery and development of ebolavirus therapeutics. Expert Opinion on Drug Discovery, 2011, 6, 233-250.	5.0	24
185	Post-Intoxication Inhibition of Botulinum Neurotoxin Serotype A within Neurons by Small-Molecule, Non-Peptidic Inhibitors. Toxins, 2011, 3, 207-217.	3.4	24
186	Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery. Expert Review of Molecular Diagnostics, 2014, 14, 153-168.	3.1	24
187	Applications of In Vivo Imaging in the Evaluation of the Pathophysiology of Viral and Bacterial Infections and in Development of Countermeasures to BSL3/4 Pathogens. Molecular Imaging and Biology, 2015, 17, 4-17.	2.6	24
188	Delayed Time-to-Treatment of an Antisense Morpholino Oligomer Is Effective against Lethal Marburg Virus Infection in Cynomolgus Macaques. PLoS Neglected Tropical Diseases, 2016, 10, e0004456.	3.0	24
189	Bithionol blocks pathogenicity of bacterial toxins, ricin and Zika virus. Scientific Reports, 2016, 6, 34475.	3.3	24
190	Sorafenib Impedes Rift Valley Fever Virus Egress by Inhibiting Valosin-Containing Protein Function in the Cellular Secretory Pathway. Journal of Virology, 2017, 91, .	3.4	24
191	Repurposing potential of 1st generation H1-specific antihistamines as anti-filovirus therapeutics. Antiviral Research, 2018, 157, 47-56.	4.1	24
192	The C Terminus of the Catalytic Domain of Type A Botulinum Neurotoxin May Facilitate Product Release from the Active Site. Journal of Biological Chemistry, 2013, 288, 24223-24233.	3.4	23
193	Histology, immunohistochemistry, and in situ hybridization reveal overlooked Ebola virus target tissues in the Ebola virus disease guinea pig model. Scientific Reports, 2018, 8, 1250.	3.3	23
194	Divergence of Human and Nonhuman Primate Lymphocyte Responses to Bacterial Superantigens. Clinical Immunology and Immunopathology, 1995, 76, 248-254.	2.0	22
195	Integrated Bioassays in Microfluidic Devices: Botulinum Toxin Assays. Journal of Biomolecular Screening, 2005, 10, 788-794.	2.6	22
196	An all-atom model of the pore-like structure of hexameric VP40 from Ebola: Structural insights into the monomerâ€“hexamer transition. Journal of Structural Biology, 2005, 151, 30-40.	2.8	22
197	Reduced Levels of Protein Tyrosine Phosphatase CD45 Protect Mice from the Lethal Effects of Ebola Virus Infection. Cell Host and Microbe, 2009, 6, 162-173.	11.0	22
198	Iterative Structure-Based Peptide-Like Inhibitor Design against the Botulinum Neurotoxin Serotype A. PLoS ONE, 2010, 5, e11378.	2.5	22

#	Article	IF	Citations
199	The Impact of Regulations, Safety Considerations and Physical Limitations on Research Progress at Maximum Biocontainment. Viruses, 2012, 4, 3932-3951.	3.3	22
200	The synthesis of 2,5-bis(4-amidinophenyl)thiophene derivatives providing submicromolar-range inhibition of the botulinum neurotoxin serotype A metalloprotease. European Journal of Medicinal Chemistry, 2012, 53, 374-379.	5.5	22
201	Reidentification of Ebola Virus E718 and ME as Ebola Virus/H.sapiens-tc/COD/1976/Yambuku-Ecran. Genome Announcements, 2014, 2, .	0.8	22
202	Implementation of Objective PASC-Derived Taxon Demarcation Criteria for Official Classification of Filoviruses. Viruses, 2017, 9, 106.	3.3	22
203	High degree of correlation between Ebola virus BSL-4 neutralization assays and pseudotyped VSV BSL-2 fluorescence reduction neutralization test. Journal of Virological Methods, 2018, 254, 1-7.	2.1	22
204	Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms. Journal of Infectious Diseases, 2018, 218, S553-S564.	4.0	22
205	Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo. Antiviral Research, 2019, 171, 104592.	4.1	22
206	Recent Advances in Botulinum Neurotoxin Inhibitor Development. Current Topics in Medicinal Chemistry, 2014, 14, 2044-2061.	2.1	22
207	TrkA In Vivo Function Is Negatively Regulated by Ubiquitination. Journal of Neuroscience, 2014, 34, 4090-4098.	3.6	21
208	Virus-Like Particles Activate Type I Interferon Pathways to Facilitate Post-Exposure Protection against Ebola Virus Infection. PLoS ONE, 2015, 10, e0118345.	2.5	21
209	Persistence of Zinc-Binding Bacterial Superantigens at the Surface of Antigen-Presenting Cells Contributes to the Extreme Potency of These Superantigens as T-Cell Activators. Infection and Immunity, 2005, 73, 5358-5366.	2.2	20
210	Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses. Expert Opinion on Drug Discovery, 2012, 7, 613-632.	5.0	20
211	Cross-Protection Conferred by Filovirus Virus-Like Particles Containing Trimeric Hybrid Glycoprotein. Viral Immunology, 2015, 28, 62-70.	1.3	20
212	Ribavirin Had Demonstrable Effects on the Crimean-Congo Hemorrhagic Fever Virus (CCHFV) Population and Load in a Patient With CCHF Infection. Journal of Infectious Diseases, 2018, 217, 1952-1956.	4.0	20
213	Assembly of Ebola Virus Matrix Protein VP40 Is Regulated by Latch-Like Properties of N and C Terminal Tails. PLoS ONE, 2012, 7, e39978.	2.5	19
214	A race for an Ebola vaccine: promises and obstacles. Trends in Microbiology, 2015, 23, 65-66.	7.7	19
215	Identification of RUVBL1 and RUVBL2 as Novel Cellular Interactors of the Ebola Virus Nucleoprotein. Viruses, 2019, 11, 372.	3.3	19
216	Antisense treatments for biothreat agents. Current Opinion in Molecular Therapeutics, 2006, 8, 93-103.	2.8	19

#	Article	IF	Citations
217	Anthrax toxin-induced rupture of artificial lipid bilayer membranes. Journal of Chemical Physics, 2013, 139, 065101.	3.0	18
218	Mechanisms of Immunity in Post-Exposure Vaccination against Ebola Virus Infection. PLoS ONE, 2015, 10, e0118434.	2.5	18
219	Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges). Viruses, 2016, 8, 94.	3.3	18
220	Zika Virus Infection in Syrian Golden Hamsters and Strain 13 Guinea Pigs. American Journal of Tropical Medicine and Hygiene, 2018, 98, 864-867.	1.4	18
221	Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR. Bioorganic and Medicinal Chemistry, 2010, 18, 2123-2130.	3.0	17
222	High-Content Imageâ€"Based Screening of a Signal Transduction Pathway Inhibitor Small-Molecule Library against Highly Pathogenic RNA Viruses. Journal of Biomolecular Screening, 2015, 20, 141-152.	2.6	17
223	Possibility and Challenges of Conversion of Current Virus Species Names to Linnaean Binomials. Systematic Biology, 2016, 66, syw096.	5.6	17
224	Antiviral therapeutics for the treatment of Ebola virus infection. Current Opinion in Pharmacology, 2016, 30, 138-143.	3.5	17
225	Correlation of body temperature with protection against staphylococcal enterotoxin B exposure and use in determining vaccine dose-schedule. Vaccine, 2003, 21, 2791-2796.	3.8	16
226	Pharmacophore Refinement Guides the Design of Nanomolar-Range Botulinum Neurotoxin Serotype A Light Chain Inhibitors. ACS Medicinal Chemistry Letters, 2010, 1, 301-305.	2.8	16
227	High Content Image Based Analysis Identifies Cell Cycle Inhibitors as Regulators of Ebola Virus Infection. Viruses, 2012, 4, 1865-1877.	3.3	16
228	Characterization of the murine macrophage response to infection with virulent and avirulent Burkholderia species. BMC Microbiology, 2015, 15, 259.	3.3	16
229	Characterization of Ebola Virus Disease (EVD) in Rhesus Monkeys for Development of EVD Therapeutics. Viruses, 2020, 12, 92.	3.3	16
230	Dominance of human innate immune responses in primary Francisella tularensis live vaccine strain vaccination. Journal of Allergy and Clinical Immunology, 2006, 117, 1186-1188.	2.9	15
231	Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors. Bioorganic and Medicinal Chemistry, 2011, 19, 7338-7348.	3.0	15
232	Therapeutics for filovirus infection: traditional approaches and progress towardsin silicodrug design. Expert Opinion on Drug Discovery, 2012, 7, 935-954.	5.0	15
233	Characterization of the Burkholderia thailandensis SOS Response by Using Whole-Transcriptome Shotgun Sequencing. Applied and Environmental Microbiology, 2013, 79, 5830-5843.	3.1	15
234	Pre-symptomatic diagnosis and treatment of filovirus diseases. Frontiers in Microbiology, 2015, 6, 108.	3.5	15

#	Article	IF	Citations
235	Validation of the Filovirus Plaque Assay for Use in Preclinical Studies. Viruses, 2016, 8, 113.	3.3	15
236	Glucopyranosyl lipid adjuvant enhances immune response to Ebola virus-like particle vaccine in mice. Vaccine, 2019, 37, 3902-3910.	3.8	15
237	Second generation of diazachrysenes: Protection of Ebola virus infected mice and mechanism of action. European Journal of Medicinal Chemistry, 2019, 162, 32-50.	5.5	15
238	Shedding Light on Filovirus Infection with High-Content Imaging. Viruses, 2012, 4, 1354-1371.	3.3	14
239	A high-content imaging assay for the quantification of the Burkholderia pseudomallei induced multinucleated giant cell (MNGC) phenotype in murine macrophages. BMC Microbiology, 2014, 14, 98.	3.3	14
240	A thermostable, chromatographically purified Ebola nano-VLP vaccine. Journal of Translational Medicine, 2015, 13, 228.	4.4	14
241	Heat fixation inactivates viral and bacterial pathogens and is compatible with downstream MALDI mass spectrometry tissue imaging. BMC Microbiology, 2015, 15, 101.	3.3	14
242	T-705 induces lethal mutagenesis in Ebola and Marburg populations in macaques. Antiviral Research, 2019, 170, 104529.	4.1	14
243	Chemical Genetic Screening Identifies Critical Pathways in Anthrax Lethal Toxin-Induced Pathogenesis. Chemistry and Biology, 2007, 14, 245-255.	6.0	13
244	Development and characterization of rabbit and mouse antibodies against ebolavirus envelope glycoproteins. Journal of Virological Methods, 2011, 174, 99-109.	2.1	13
245	A Limited Structural Modification Results in a Significantly More Efficacious Diazachrysene-Based Filovirus Inhibitor. Viruses, 2012, 4, 1279-1288.	3.3	13
246	PREDICTIVE SYSTEMS BIOLOGY APPROACH TO BROAD-SPECTRUM, HOST-DIRECTED DRUG TARGET DISCOVERY IN INFECTIOUS DISEASES. , 2012, , .		13
247	Src Family Kinase Inhibitors Antagonize the Toxicity of Multiple Serotypes of Botulinum Neurotoxin in Human Embryonic Stem Cell-Derived Motor Neurons. Neurotoxicity Research, 2015, 27, 384-398.	2.7	13
248	Development of a liquid chromatography high resolution mass spectrometry method for the quantitation of viral envelope glycoprotein in Ebola virus-like particle vaccine preparations. Clinical Proteomics, 2016, 13, 18.	2.1	13
249	T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection. Emerging Microbes and Infections, 2017, 6, 1-9.	6.5	13
250	Clinical Laboratory Values as Early Indicators of Ebola Virus Infection in Nonhuman Primates. Emerging Infectious Diseases, 2017, 23, 1316-1324.	4.3	13
251	Virulence of Marburg Virus Angola Compared to Mt. Elgon (Musoke) in Macaques: A Pooled Survival Analysis. Viruses, 2018, 10, 658.	3.3	13
252	Ebola Virus Causes Intestinal Tract Architectural Disruption and Bacterial Invasion in Non-Human Primates. Viruses, 2018, 10, 513.	3.3	13

#	Article	IF	Citations
253	Inhibition of interleukin-2-stimulated enhancement of human natural killer (NK) cell activity by carbaryl, an anticholinesterase insecticide. Toxicology Letters, 1992, 63, 299-311.	0.8	12
254	A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of Î± chain, Î² chain, and antigenic peptide, with immunogenicityin vitro and reduced affinity for bacterial superantigens. European Journal of Immunology, 1997, 27, 1933-1941.	2.9	12
255	Induced IL-10 Splice Altering Approach to Antiviral Drug Discovery. Nucleic Acid Therapeutics, 2014, 24, 179-185.	3.6	12
256	Current Status of Chemically Synthesized Inhibitors of Ebola Virus. Recent Patents on Anti-infective Drug Discovery, 2015, 9, 97-103.	0.8	12
257	Generation of heterogeneous memory T cells by live attenuated tularemia vaccine in humans. Vaccine, 2009, 28, 195-206.	3.8	11
258	The Osmolyte Trimethylamine N-Oxide (TMAO) Increases the Proteolytic Activity of Botulinum Neurotoxin Light Chains A, B, and E: Implications for Enhancing Analytical Assay Sensitivity. Journal of Biomolecular Screening, 2010, 15, 928-936.	2.6	11
259	Analysis of botulinum neurotoxin serotype A metalloprotease inhibitors: analogs of a chemotype for therapeutic development in the context of a three-zone pharmacophore. Open Access Bioinformatics, 2010, 2010, 11.	0.9	11
260	Peptide Conjugated Phosphorodiamidate Morpholino Oligomers Increase Survival of Mice Challenged with AmesBacillus anthracis. Nucleic Acid Therapeutics, 2012, 22, 316-322.	3.6	11
261	A reverse-phase protein microarray-based screen identifies host signaling dynamics upon Burkholderia spp. infection. Frontiers in Microbiology, 2015, 6, 683.	3.5	11
262	Considerations for the development of Zika virus vaccines. Vaccine, 2016, 34, 3711-3712.	3.8	11
263	Modeling mosquito-borne and sexual transmission of Zika virus in an enzootic host, the African green monkey. PLoS Neglected Tropical Diseases, 2020, 14, e0008107.	3.0	11
264	Searching for Therapeutics Against Botulinum Neurotoxins: A True Challenge for Drug Discovery. Current Topics in Medicinal Chemistry, 2016, 16, 2330-2349.	2.1	11
265	Synthesis and Biological Evaluation of Inhibitors of Botulinum Neurotoxin Metalloprotease. Heterocycles, 2009, 79, 487.	0.7	10
266	Filovirus infections. Journal of the American Veterinary Medical Association, 2009, 234, 1130-1139.	0.5	10
267	Asymptomatic Ebola virus infectionsâ€"myth or reality?. Lancet Infectious Diseases, The, 2017, 17, 570-571.	9.1	10
268	Adjuvant selection impacts the correlates of vaccine protection against Ebola infection. Vaccine, 2020, 38, 4601-4608.	3.8	10
269	Exosomes originating from infection with the cytoplasmic single-stranded RNA virus Rift Valley fever virus (RVFV) protect recipient cells by inducing RIG-I mediated IFN-B response that leads to activation of autophagy. Cell and Bioscience, 2021, 11, 220.	4.8	10
270	Discovery of common marburgvirus protective epitopes in a BALB/c mouse model. Virology Journal, 2009, 6, 132.	3.4	9

#	Article	IF	Citations
271	Viral diversity and clonal evolution from unphased genomic data. BMC Genomics, 2014, 15, S17.	2.8	9
272	Host response during Yersinia pestis infection of human bronchial epithelial cells involves negative regulation of autophagy and suggests a modulation of survival-related and cellular growth pathways. Frontiers in Microbiology, 2015, 6, 50.	3.5	9
273	Biochip for the Detection of Bacillus anthracis Lethal Factor and Therapeutic Agents against Anthrax Toxins. Membranes, 2016, 6, 36.	3.0	9
274	Treatment-focused Ebola trials, supportive care and future of filovirus care. Expert Review of Anti-Infective Therapy, 2018, 16, 67-76.	4.4	9
275	Characterization of the plasma proteome of nonhuman primates during Ebola virus disease or melioidosis: a host response comparison. Clinical Proteomics, 2019, 16, 7.	2.1	9
276	Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus. Scientific Reports, 2021, 11, 19458.	3.3	9
277	Eastern equine encephalitis virus rapidly infects and disseminates in the brain and spinal cord of cynomolgus macaques following aerosol challenge. PLoS Neglected Tropical Diseases, 2022, 16, e0010081.	3.0	9
278	Novel benzimidazole inhibitors of botulinum neurotoxin/A display enzyme and cell-based potency. Botulinum Journal, 2011, 2, 16.	0.2	8
279	The International Code of Virus Classification and Nomenclature (ICVCN): proposal for text changes for improved differentiation of viral taxa and viruses. Archives of Virology, 2013, 158, 1621-1629.	2.1	8
280	United States FDAâ€™s emergency use authorization of Ebola virus diagnostics: current impact and lessons for the future. Expert Review of Molecular Diagnostics, 2015, 15, 1231-1235.	3.1	8
281	Quantitative Analysis of Repertoire-Scale Immunoglobulin Properties in Vaccine-Induced B-Cell Responses. Frontiers in Immunology, 2017, 8, 910.	4.8	8
282	Low potential for mechanical transmission of Ebola virus via house flies (Musca domestica). Parasites and Vectors, 2017, 10, 218.	2.5	8
283	Avoidance behavior independent of innate-immune signaling seen in Caenorhabditis elegans challenged with Bacillus anthracis. Developmental and Comparative Immunology, 2020, 102, 103453.	2.3	8
284	Mutational effects on protein folding stability and antigenicity: the case of streptococcal pyrogenic exotoxin A. Clinical Immunology, 2003, 108, 60-68.	3.2	7
285	Integrating High-Content Imaging and Chemical Genetics to Probe Host Cellular Pathways Critical for Yersinia Pestis Infection. PLoS ONE, 2013, 8, e55167.	2.5	7
286	Novel therapeutic uses and formulations of botulinum neurotoxins: a patent review (2012 â€“ 2014). Expert Opinion on Therapeutic Patents, 2015, 25, 675-690.	5.0	7
287	New Steroidal 4-Aminoquinolines Antagonize Botulinum Neurotoxin Serotype A in Mouse Embryonic Stem Cell Derived Motor Neurons in Postintoxication Model. Journal of Medicinal Chemistry, 2018, 61, 1595-1608.	6.4	7
288	- Vascular Endothelium and Hemorrhagic Fever Viruses. , 2016, , 64-83.		7

#	Article	IF	Citations
289	Therapeutic potential of the heme oxygenase-1 inducer hemin against Ebola virus infection. Current Trends in Immunology, 2016, 17, 117-123.	4.0	7
290	Characterization of a putative filovirus vaccine: Virus-like particles. Virologica Sinica, 2013, 28, 65-70.	3.0	6
291	Bis-imidazolinylindoles are active against methicillin-resistant Staphylococcus aureus and multidrug-resistant Mycobacterium tuberculosis. Journal of Antibiotics, 2013, 66, 47-49.	2.0	6
292	Broad-spectrum Investigational Agent GS-5734 for the Treatment of Ebola, MERS Coronavirus and Other Pathogenic Viral Infections with High Outbreak Potential. Open Forum Infectious Diseases, 2017, 4, S737-S737.	0.9	6
293	The utilization of advance telemetry to investigate critical physiological parameters including electroencephalography in cynomolgus macaques following aerosol challenge with eastern equine encephalitis virus. PLoS Neglected Tropical Diseases, 2021, 15, e0009424.	3.0	6
294	Phosphatase Inhibitors Function as Novel, Broad Spectrum Botulinum Neurotoxin Antagonists in Mouse and Human Embryonic Stem Cell-Derived Motor Neuron-Based Assays. PLoS ONE, 2015, 10, e0129264.	2.5	6
295	A theoretical study of anthrax lethal factor inhibition by a set of novel carbamimidolyl-aryl-vinyl-carboxamidines: A possible mechanism involving zinc-ligation by amidine. Computational and Theoretical Chemistry, 2007, 821, 139-144.	1.5	5
296	The International Code of Virus Classification and Nomenclature (ICVCN): proposal to delete Rule 3.41. Archives of Virology, 2013, 158, 297-299.	2.1	5
297	New 9-aminoacridine derivatives as inhibitors of Botulinum neurotoxins and P. falciparum malaria. Journal of the Serbian Chemical Society, 2013, 78, 1847-1864.	0.8	5
298	Nonhuman Transferrin Receptor 1 Is an Efficient Cell Entry Receptor for Ocozocoautla de Espinosa Virus. Journal of Virology, 2013, 87, 13930-13935.	3.4	5
299	Posterior Segment Ophthalmic Manifestations in Ebola Survivors, Sierra Leone. Ophthalmology, 2021, 128, 1371-1373.	5.2	5
300	Viral Hemorrhagic Fevers. , 2013, , 3-14.		5
301	Clinical Laboratory Values in Human Ebola Virus Disease Support the Relevance of the Intramuscular Ebola-Kikwit Rhesus Model. Clinical Infectious Diseases, 2018, 66, 1479-1480.	5.8	4
302	Pre-positioned Outbreak Research: The Joint Medical Emerging Diseases Intervention Clinical Capability Experience in Uganda. Health Security, 2020, 18, 114-124.	1.8	4
303	Is there space for a three-dose vaccine to fight the spread of SARS-CoV-2?. Lancet Infectious Diseases, The, 2021, 21, 1054-1055.	9.1	4
304	Screening of a Focused Ubiquitin-Proteasome Pathway Inhibitor Library Identifies Small Molecules as Novel Modulators of Botulinum Neurotoxin Type A Toxicity. Frontiers in Pharmacology, 2021, 12, 763950.	3.5	4
305	A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors. Journal of Visualized Experiments, 2014, , e51915.	0.3	3
306	Countering Zika Virus: The USAMRIID Response. Advances in Experimental Medicine and Biology, 2018, 1062, 303-318.	1.6	3

#	Article	IF	Citations
307	Intensive Care Unitâ€"Like Care of Nonhuman Primates with Ebola Virus Disease. Journal of Infectious Diseases, 2021, 224, 632-642.	4.0	3
308	Emerging therapeutic options against filoviruses. Drugs of the Future, 2012, 37, 343.	0.1	3
309	The rapidly advancing field of biodefense benefits many other, critical public health concerns. Discovery Medicine, 2005, 5, 371-7.	0.5	3
310	Toward RNA interferenceâ€based therapy for filovirus infections. Drug Development Research, 2009, 70, 246-254.	2.9	2
311	Approach to Cataract Surgery in an Ebola Virus Disease Survivor with Prior Ocular Viral Persistence. Emerging Infectious Diseases, 2020, 26, 1553-1556.	4.3	2
312	Alveolar Macrophages Infected with Ames or Sterne Strain of Bacillus anthracis Elicit Differential Molecular Expression Patterns. PLoS ONE, 2014, 9, e87201.	2.5	2
313	Inhibition of Human Serum Complement Activity by Diisopropylfluorophosphate and Selected Anticholinesterase Insecticides. Toxicological Sciences, 1989, 12, 460-468.	3.1	1
314	Retrovirus-Based Surrogate Systems for BSL-2 High-Throughput Screening of Antivirals Targeting BSL-3/4 Hemorrhagic Fever-Causing Viruses. Methods in Molecular Biology, 2018, 1604, 393-403.	0.9	1
315	Chimpanzee adenovirus type 3 vectored Ebola vaccine: expanding the field. Lancet Infectious Diseases, The, 2020, 20, 636-637.	9.1	1
316	Emerging options in development for treatment of filovirus infections. Drugs of the Future, 2015, 40, 0727.	0.1	1
317	Viral Hemorrhagic Fevers. , 2005, , 227-257.		1
318	In Vivo and In Vitro Characterization of Provodine, a Long Acting, Alcohol-Free Professional Antiseptic, Against Ebola Virus and Other Serious Viral, Bacterial and Fungal Pathogens. Open Forum Infectious Diseases, 2015, 2, .	0.9	1
319	A Novel Toll-Like Receptor 2 Agonist Protects Mice in a Prophylactic Treatment Model Against Challenge With Bacillus anthracis. Frontiers in Microbiology, 2022, 13, 803041.	3.5	1
320	Development of High Content Imaging Assays for Lethal Viral Pathogens. Microscopy and Microanalysis, 2010, 16, 650-651.	0.4	0
321	High Content Imaging for Discovery of Botulinum Neurotoxin Antagonists. Microscopy and Microanalysis, 2010, 16, 648-649.	0.4	0
322	Treatment of highly pathogenic filovirus infections using advanced antisense technology. Retrovirology, 2010, 7, .	2.0	0
323	Detection of Highly Pathogenic Viral Agents. , 2010, , 417-429.		0
324	Identification of novel microRNA biomarkers of viral infection. International Journal of Infectious Diseases, 2010, 14, e364.	3.3	0

#	Article	IF	Citations
325	High-Content Imaging to Profile Cellular and Pathogen Responses to Bioactive Probes. Microscopy and Microanalysis, 2011, 17, 1126-1127.	0.4	0
326	203. Development of an electrochemiluminescent assay to support high-throughput screening for botulinum neurotoxin serotype A (BoNT/A) inhibitors. Toxicon, 2015, 93, S63.	1.6	0
327	- Interaction of the Host Immune System with Hemorrhagic Fever Viruses. , 2016, , 52-63.		0
328	Ebolaâ€™s exploits: debilitating host immune responses through interferon inhibiting domains. Journal of Public Health and Emergency, 0, 1, 45-45.	4.4	0